Carotenoid analogs or derivatives for controlling connexin 43 expression

US7763649B2 · kind B2 · utility

Assignee

• Cardax Pharmaceuticals, Inc. · US

Inventors

• Samuel Lockwood · Lake Linden, US
• Sean O'Malley · Honolulu, US
• David G. Watumull · Honolulu, US
• Laura M. Hix · San Francisco, US
• Henry Jackson · Honolulu, US
• Geoff Nadolski · Kaaawa, US

Key dates

• Filing date: Mar 4, 2004
• Grant date: Jul 27, 2010
• Expiry date: Mar 21, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H13/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.